Nanohale AG (ETR:FYB) | WebDisclosure

Basculer en Français

10404	Companies
217474	Keywords
147078	Articles
115108	Press releases

Home
Companies
Nanohale AG

PRESS RELEASE

published on 07/26/2024 at 12:00, 1 year 9 months ago

Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®
Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 biosimilar candidate to Stelara. Approval expected in early Q4 2024. Biosimilars boost healthcare access & reduce costs globally

Biosimilar Formycon Fresenius Kabi FYB202 CHMP Opinion
BRIEF

published on 07/26/2024 at 10:59, 1 year 9 months ago

FYB202 Biosimilar to Stelara Receives Positive CHMP Opinion from EMA

Biosimilar Formycon FYB202 CHMP EMA
BRIEF

published on 07/26/2024 at 10:59, 1 year 9 months ago

Le biosimilaire FYB202 de Stelara reçoit un avis positif du CHMP de l'EMA

Formycon FYB202 Biosimilaire CHMP EMA
PRESS RELEASE

published on 07/26/2024 at 10:54, 1 year 9 months ago

EQS-Adhoc: Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA
Formycon AG's biosimilar candidate FYB202 (Ustekinumab) for Stelara® receives a positive opinion from EMA's CHMP, recommended for EU approval for treating severe inflammatory diseases

Formycon AG Biosimilar FYB202 CHMP EMA
BRIEF

published on 07/01/2024 at 06:55, 1 year 10 months ago

Formycon Receives FDA Approval for Aflibercept Biosimilar

FDA Approval Biosimilar Formycon Retinal Diseases Ophthalmic Therapies
BRIEF

published on 07/01/2024 at 06:55, 1 year 10 months ago

Formycon reçoit l'approbation de la FDA pour le biosimilaire Aflibercept

Approbation De La FDA Formycon Biosimilaire Maladies De La Rétine Thérapies Ophtalmiques
PRESS RELEASE

published on 07/01/2024 at 06:50, 1 year 10 months ago

Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)
Formycon receives FDA approval for FYB203/AHZANTIVE(R) (aflibercept-mrbb), a biosimilar to Eylea(R). The approval highlights Formycon's expertise and commitment to providing effective and affordable biosimilar therapies for retinal diseases.

FDA Approval Biosimilar Formycon Eylea Retinal Diseases
BRIEF

published on 06/28/2024 at 23:55, 1 year 10 months ago

FDA Approves Biosimilar FYB203/AHZANTIVE® for Retinal Diseases

FDA Approval Biosimilar Eylea Retinal Diseases Treatment Approval
BRIEF

published on 06/28/2024 at 23:55, 1 year 10 months ago

La FDA approuve le biosimilaire FYB203/AHZANTIVE® pour les maladies rétiniennes

Approbation De La FDA Biosimilaire Eylea Maladies De La Rétine Approbation Du Traitement
PRESS RELEASE

published on 06/28/2024 at 23:50, 1 year 10 months ago

EQS-Adhoc: FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
FDA grants approval for Eylea biosimilar FYB203/AHZANTIVE by Formycon AG and Klinge Biopharma GmbH. Biosimilar approved for nAMD and other retinal diseases

FDA Approval Retinal Diseases Eylea Biosimilar FYB203/AHZANTIVE Neovascular Age-Related Macular Degeneration

Accesswire

Published on 05/14/2026 at 13:00, 23 minutes ago

Eagle Plains and Sun Summit Make Greenfields Discovery at the Orbit Project, Toodoggone District, BC.
Published on 05/14/2026 at 13:00, 23 minutes ago

Aztec Drilling Expands Oxide Gold-Silver Zone Step Outs at Tombstone; intersecting 2.31 gpt Au and 43.23 gpt Ag over 27.4 m within 66.9 m of 1.05 gpt Au and 23.21 gpt Ag
Published on 05/14/2026 at 12:58, 25 minutes ago

BlackBerry to Participate in Upcoming Investor Events
Published on 05/14/2026 at 12:30, 53 minutes ago

L Catterton, LVMH’s Investment Arm, Forms Strategic Partnership with Saint Bella Group to Fast Track Global Brand Growth
Published on 05/14/2026 at 12:00, 1 hour 23 minutes ago

SouthGobi Announces First Quarter 2026 Financial and Operating Results

View all ACCESSWIRE

EQS Group

Published on 05/14/2026 at 12:51, 31 minutes ago

Edison issues report on VietNam Holding (VNH)
Published on 05/14/2026 at 12:50, 32 minutes ago

Oritain Launches Landmark 2026 Global Supply Chain Intelligence Report
Published on 05/14/2026 at 12:20, 1 hour 2 minutes ago

YASH Technologies Recognized as a Major Contender in Everest Group's Digital Workplace Services PEAK Matrix® Assessment 2026 - Mid-market Enterprises
Published on 05/14/2026 at 11:57, 1 hour 26 minutes ago

Thalassa Holdings Ltd: Notice of AGM
Published on 05/14/2026 at 11:45, 1 hour 38 minutes ago

Fuutura launches non-custodial multi-asset trading protocol with identity attestation at the protocol layer

Les Echos

Published on 05/14/2026 at 09:03, 4 hours 20 minutes ago

Coup d'envoi pour les carrières dans l'esport : 65% de la population mondiale réclame plus de formations et de parcours professionnels pour le jeu vidéo de compétition
Published on 05/13/2026 at 18:02, 19 hours 20 minutes ago

ALTAREA : Assemblée Générale Mixte du 4 juin 2026 MODALITES DE MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES
Published on 05/13/2026 at 18:00, 19 hours 23 minutes ago

DDV monthly statement at April 30 2026
Published on 05/13/2026 at 18:00, 19 hours 23 minutes ago

DDV declaration au 30 avril 2026
Published on 05/13/2026 at 18:00, 19 hours 23 minutes ago

ALTAREIT - Assemblée Générale Mixte du 4 juin 2026 - Modalités de mise à disposition des documents préparatoires

View all LES ECHOS COMFI WIRE